Reply to comment on “Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?”

[1]  Erkan Cüre,et al.  Comment on “Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?” , 2020, Diabetes Research and Clinical Practice.

[2]  Ying Jie Chee,et al.  Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus , 2020, Diabetes Research and Clinical Practice.

[3]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[4]  S. Bhadada,et al.  Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? , 2020, Diabetes Research and Clinical Practice.

[5]  S. Goh,et al.  Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors , 2019, Clinical Drug Investigation.

[6]  S. Efrati,et al.  Lactic acidosis and severe septic shock in metformin users: a cohort study , 2015, Critical Care.

[7]  L. Shimoda,et al.  Na+/H+ Exchange and Hypoxic Pulmonary Hypertension , 2015, Pulmonary circulation.

[8]  N. Grobe,et al.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. , 2014, American journal of physiology. Renal physiology.

[9]  R. Misbin.  The phantom of lactic acidosis due to metformin in patients with diabetes. , 2004, Diabetes care.

[10]  G. Koliakos,et al.  The Effect of Insulin on Na+-H+ Antiport Activity of Obese and Normal Subjects Erythrocytes , 2001, Cellular Physiology and Biochemistry.